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ABSTRACT
HIV-1 integrase (IN) is the key enzyme catalyzing the
proviral DNA integration step. Although the enzyme
catalyzes the integration step accurately in vitro,
whether IN is sufficient for in vivo integration and
how it interacts with the cellular machinery remains
unclear. We set up a yeast cellular integration sys-
tem where integrase was expressed as the sole
HIV-1 protein and targeted the chromosomes. In this
simple eukaryotic model, integrase is necessary and
sufficient for the insertion of a DNA containing viral
LTRs into the genome, thereby allowing the study of
the isolated integration step independently of other
viral mechanisms. Furthermore, the yeast system
was used to identify cellular mechanisms involved
in the integration step and allowed us to show the
role of homologous recombination systems. We
demonstrated physical interactions between HIV-1
IN and RAD51 protein and showed that HIV-1
integrase activity could be inhibited both in the cell
and in vitro by RAD51 protein. Our data allowed the
identification of RAD51 as a novel in vitro IN
cofactor able to down regulate the activity of this
retroviral enzyme, thereby acting as a potential
cellular restriction factor to HIV infection.
INTRODUCTION
Retroviral integration is mediated by the preintegration
complex (PIC) whose composition has not yet been com-
pletely elucidated. HIV-1 integrase (IN) is a major compo-
nent of the PIC and is necessary and sufﬁcient for the
integration reaction in vitro (1, 2). Although recombinant
IN can efﬁciently perform both 30-processing and the
insertion of one viral extremity in vitro, some differences in
the integration activity of the recombinant protein and its
activity in the partially puriﬁed PIC have been described.
Several cellular factors associated with the PIC, such as the
high mobility group protein HMGA1, the transcription factor
INI1 or LEDGF/p75, have been shown to stimulate in vitro
integration reactions and/or play an important role in the
HIV-1 infection cycle (3–7). The lack of these factors in
the in vitro integration assays may account for the differences
observed between these two systems. However, it has
recently been reported that recombinant IN, puriﬁed under
certain conditions, performed a concerted integration reaction
which was almost as efﬁcient as that catalyzed by the PIC (8).
Thus we investigated herein whether IN might be the minimal
viral protein required for integration in a cellular context.
Previous attempts to evaluate the activity of HIV-1 IN
over-expressed in eukaryotic cells failed to describe any
speciﬁc integration (9). We have previously described a
yeast eukaryotic model in which HIV-1 IN expressed as the
sole viral protein produces a lethal effect linked to its previ-
ously described non-sequence-speciﬁc endonucleolytic activ-
ity (10–12). We, thus, established a system based on this
model, thereby allowing the analysis of the integration step
independently of other viral mechanisms.
Here we report for the ﬁrst time that HIV-1 IN expressed as
the sole retroviral protein in eukaryotic cells was sufﬁcient to
catalyze the complete integration of a DNA containing two
viral LTRs into the nuclear genome. Using this model, we
demonstrated the RAD51 dependent pathway of homologous
recombination (HR) down regulates the integration activities
catalyzed by IN both in vitro and in yeast.
MATERIALS AND METHODS
Yeast strains, culture media and growth conditions
Yeast strains The nomenclature used for the yeast strains
was previously described (11). The following haploid yeast
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+) (MATa, ura3-52,
leu2-3,112, ade2-1, his3-11, 15, trp1-1); W839-5C
(h.rad52
 ) (isogenic to W3031A except rad52::TRP1);
BY4742Drad18 (h.rad18
 )( MATa, ura3D0, leu2D0, lys2D0,
his3D1, rad18::kanMX4); BY4742Drad51 (h.rad51) (MATa,
ura3D0, leu2D0, lys2D0, his3D1, rad51::kanMX4).
Culture media Yeast selective media: YNB lacking uracil
and leucine (0.67% yeast nitrogen base without amino acids,
0.1–8% glucose); YCAD lacking uracil (YNB 2% glucose
supplemented with 0.5% casamino acids). Amino acids and
bases (20–30 mg/l) were added as required. For the selection
of zeocin-resistant cells, YCAD was supplemented with
400 mg/ml zeocin (INVITROGEN).
Growth conditions Liquid cultures were performed in
Erlenmeyer ﬂasks ﬁlled to a ﬁfth of their capacity and then
shaken. Solid media were obtained by supplementing liquid
media with 2% bacto-agar. Yeast strains were grown at 30 C.
DNA materials
All DNA vectors and PCR products were puriﬁed using DNA
puriﬁcation systems from PROMEGA (Wizard plus SV mini-
prep and Wizard SV Gel kits). PCR ampliﬁcations were
done under standard conditions using Taq polymerase
(PROMEGA).
Expression vectors The HIV-1 IN gene was obtained from a
cloned genomic provirus of a San Francisco isolate (SF2) (13).
pHIV1SF2IN and pHIV1SF2IN-D116A were derived from
the yeast/Escherichia coli shuttle plasmid pBS24.1 described
previously (10).
DNA substrates of the yeast integration assay Various
DNAs were used: (i) A 1212 bp double-stranded linear
DNA ﬂanked by the two sequences mimicking the HIV-1
U3 and U5 viral ends carries the zeocin-resistance encoding
gene under the control of the yeast TEF1 promoter. This frag-
ment was generated by PCR on pTEF1/Zeo vector (INVIT-
ROGEN) using primers 50-U3-Zeo (50-ACTGGA
AGGGGCTAATTCACCCCACACACCATAGCTTCAAAAT-
GTTTCTACTCC-30) and 30-U5-Zeo (50-ACTGCTAGAGA
TTTTCCACAAGCTTGCAAATTAAAGCCTTCGAGCGTCC-
C-30); (ii) a pre-processed substrate was prepared by PCR on
pTEF1/Zeo with primers NdeI-50-U3-Zeo (50-GGAATTC
CATATGGAAGGGCTAATTCACCCCACACACCATAGC
TTCAAAATGTTTCTACTCC-30) and NdeI-30-U5-Zeo (50-G
GAATTCCATATGCTAGAGATTTTCCACAAGCTTGCA-
AATTAAAGCCTTCGAGCGTCCC-30). The NdeI restric-
tion site is underlined. The resulting PCR product was
puriﬁed and used directly as the unprocessed integration
substrate. The ampliﬁcation product was also cloned
into pGEM-T vector according to the manufacturer’s recom-
mendations (PROMEGA) and the pGEM-T-LTR-Zeo
obtained vector was subjected to NdeI restriction cuts.
The 1212 bp insert obtained displayed the 30-OH recessed
viral ends mimicking the 30-processed LTR at each extremity;
(iii) a 1169 bp DNA fragment with no viral LTRs was
constructed by PCR ampliﬁcation on pTEF1/Zeo using the
following primers: 50-Cont-Zeo (50-CCCACACACCATAGC
TTCAAAATGTTTCTACTCC-30) and 30-Cont-Zeo (50-TTG
CAAATTAAAGCCTTCGAGCGTCCC-30). Positions of the
different primers are shown on Figure 1.
Yeast integration assay
The strategy used to follow integration of the DNA substrate
containing the viral LTRs into yeast genome is presented
in Figure 1. Yeast cells harboring either pHIV1SF2IN or
pHIV1SF2IN-D116Avectorsweregrownfor72hundermaxi-
mal expression conditions (10 ml YNB containing 0.1% glu-
cose and supplemented with required amino acids) until an
OD600nm of  10 was attained (stationary phase). Proteins
were then extracted and analyzed by SDS–PAGE in order to
determine IN expression. Yeast aliquots were used for trans-
formation with an excess of DNA substrate (7 · 10
11 mole-
cules) under conditions previously described (14). After
transformation, 10
9 viable cells calculated by counting the
number of cells recovered after plating on non-selective med-
ium were cultured in YCAD liquid medium for 0–6 h and
then plated on solid YCAD medium supplemented with zeocin
(400 mg/ml) to select the cells expressing the Sh ble gene from
the DNA substrate. After ﬁve days of culture, resistant clones
were recovered, stocked and analyzed further. Transformants
were selected on medium lacking uracil and histidine.
PCR, Southern blot and sequencing analysis of the
integration events
The chromosomal DNA from the selected zeocin-resistant
clones was prepared as described previously (15) and
then submitted to PCR ampliﬁcation using 50-pTEF1 (50-TT
CATTAGAAAGAAAGCATAGC-30) and 30-U5-Zeo pri-
mers. Under positive integration conditions, an ampliﬁcation
product of 800 bp is expected. Southern blot analysis was
performed on genomic DNA according to a previously
described protocol (16) and using BamH1 restriction enzyme
(PROMEGA) and the
32P-labeled ODN, 50-
32P-U3-Zeo
described above as probe. Sequencing was performed using
chromosomal DNA digested by BamH1, religated with T4
DNA ligase (PROMEGA) and ampliﬁed using 50-U3-junction
(50-GATGCGCGGAGTCCGA-30) and 30-U5-junction (50-AG
ACGCGTGTACGCATGTA-30) primers. The ampliﬁcation
products were used in PCR-based sequencing (ABI Prism
big dye terminator cycle sequencing ready reaction kit,
Applied Biosystems) using the same primers.
HIV-1 IN purification, in vitro IN activities and
ELISA assay
HIV-1 IN puriﬁcation and in vitro assays were described
previously (17). Human wild type RAD51 proteins were puri-
ﬁed as reported before (18) and bacterial integron class 1
recombinase IntI1 (kind gift from Pr C. Quentin) were
added in the assay when mentioned. Integration products
were quantiﬁed with ImageJ software.
ELISA experiments were done as follows. Plate wells
were coated overnight at 4 C with 30 pmol of the recombina-
tion proteins diluted in a 0.1 M carbonate solution. Wells
were washed with a solution of PBS containing 0.05%
Tween (PBS 0.05% Tween), saturated for 1 h with BSA
(10 mg/ml) and washed three times with PBS 0.05% Tween
solution. IN (30 pmol) was added and incubated for 1 h at
37 C. After washing three times with PBS 0.05% Tween,
anti-IN primary antibodies were incubated for 2 h at 37 C.
After three washings, secondary antibodies were incubated
for 1 h at 37 C and the interaction was revealed with
6216 Nucleic Acids Research, 2006, Vol. 34, No. 21Amplex-Red (Invitrogen) after washing with PBS. The
absorbance was determined at 530/590 nm.
Pull down experiments
Puriﬁed hRAD51 and BSA were coupled to Afﬁ-Gel 15 beads
(Bio-Rad) to create matrices containing 3 mg/ml of RAD51
and 12 mg/ml BSA. To examine complex formation, HIV-1
IN (4 mg) was mixed with 5 ml Afﬁ-RAD51 or Afﬁ-BSA
beads in 100 ml buffer B (25 mM Tris at pH 7.4, 0.5 mM
EDTA, 1 mM DTT, 0.01% Igepal CA-630, 75 mM NaCl
and 10% glycerol) at 4 C for 60 min. The Afﬁ-hRAD51 mix-
ture also contained 2 mg of BSA. The beads were washed twice
with 100 ml of the same buffer, before eluting the bound pro-
teins with 30 ml SDS–PAGE loading buffer. The supernatant
(S), wash (W) and SDS eluate (E), 10 ml each, were analyzed
by 12% SDS–PAGE and Coomassie blue staining.
RESULTS
HIV-1 integrase integrates a DNA carrying two LTRs
into the yeast genome
The h.RAD52
+ yeast strain expressing HIV-1 IN was grown
under optimal condition for the expression of an active
enzyme (72 h, 0.1% glucose as determined previously (10),
conﬁrmed by both western blot and in vitro activities).
To detect the integration, we implemented the strategy
shown in Figure 1. A DNA fragment containing the two
HIV-1 U3 and U5 LTRs ends ﬂanking the zeocin-resistance
encoding gene under the dependence of the yeast constitutive
TEF1 promoter was introduced by electroporation into the
cells after IN expression. Yeast cells were grown further for
1–5 h without selection to allow: (i) the interaction between
IN and its substrate, (ii) nuclear import of both DNA and IN
and (iii) integration of the DNA fragment. Approximately 10
9
viable yeast cells were then plated on a solid medium con-
taining 400 mg/ml of zeocin and the zeocin-resistant clones
were selected 5 days after plating. The ﬁrst resistant clones
were observed after 2 h of culture and the maximum number
was attained after 4–5 h (Figure 2A). Zeocin-resistance
analysis of the selected clones indicated a 100-fold increase
compared to that of the initial yeast strain, thus conﬁrming
the acquisition of resistance.
Using yeast strains expressing the inactive mutant D116A
IN or no IN only few clones were observed (Figure 2B and
C), indicating that only a minor portion of the clones obtained
with the cells expressing wild type IN (wt IN) was linked to
an IN-independent process as the putative acquisition of
mutational resistance.
Molecular analysis of the resistant clones
To conﬁrm that the zeocin-resistant clones were repre-
sentative of genuine integration events, several different
molecular assays were performed. The expected 800 bp
fragment was detected by PCR on total genomic DNA of
the clones using internal primers for all the resistant clones
obtained from h.RAD52
+ (wt IN), whereas this product was
IN
Yeast cells
expressing HIV-1 IN
IN IN
Transformation with DNA substrate
HIV-1 IN expression
Culture without zeocin during
variable times
Spreading of 109 cells on solid medium
containing zeocin
5 days after plating
selection and analysis of ZeoR clones
Yeast cells harbouring
pHIV1SF2IN, pHIV1SF2IN-D116A or pBS24.1
U3 U5 CYC1tt Zeo PTEF1
B
A
C
A’
B’
C’
D
E
E’
5’
ACTGGAAGGGGCTAATTCAC
TGACCTTCCCCGATTAAGTG
TGTGGAAAATCTCTAGCAGT
ACACCTTTTAGAGATCGTCA 5’
Figure 1. Yeast integration assay. Yeast cells (h.RAD52
+) containing pHIV1SF2IN, pHIV1SF2IN-D116A or empty pBS24.1 were grown for 3 days under
conditions of IN expression in a medium containing 0.1% glucose without leucine. Yeast cells were then transformed with the integration DNA substrate
containing the Sh Ble ORF (Zeo) flanked by the LTR sequences. Cells were grown in the absence of zeocin for variable times and then plated on solid medium
containing 400 mg/ml zeocin. Resistant clones were selected five days after plating and analyzed. PTEF1 : TEF1 promoter, CYC1tt : CYC1 transcription
termination sequence. Arrows indicate primer positions used for the generation of different substrates, PCR and Southern blot analysis: 50-U3-Zeo (A), 30-U5-Zeo
(A’), NdeI-50-U3-Zeo (B), NdeI-30-U5-Zeo (B’), 50-Cont-Zeo (C), 30-Cont-Zeo (C’), 50-pTEF1 (D), 50-U3-junction (E) and 30-U5-junction (E’).
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+ (D116A IN)
clones or with the control DNA from non IN-expressing yeast
(Figure 3A).
Southern blot analysis using 50-end (
32P) radiolabeled U3-
Zeo as probe revealed a band for h.RAD52
+(wt IN) clones
but not for h.RAD52
+ expressing D116A IN or no IN
(Figure 3B). The negative result obtained with h.RAD52
+
(D116A) clones conﬁrmed that the resistance observed in
that case was not due to integration of the substrate into the
genome but rather to another cellular mechanism.
To identify the integration loci and analyze the ﬁdelity of
integration events, total genomic DNA of 20 previously
selected clones were sequenced as described in the Materials
and Methods section. For all of these clones, the integrated
DNA was found disrupting a distinct open reading frame
(ORF) (Figure 3C shows an e.g. of the genetic structure of
the integrated fragments of the three clones analyzed in
Figure 3A and B).
Since the sequence of the junctions between integrated
LTRs and the target DNA constitutes a speciﬁc signature
of the IN involved in this process, they were carefully
analyzed. The 5 bp repeats characterizing HIV integration
were recovered for nine clones, conﬁrming that HIV-1 IN
was responsible for the process (Figure 3D). In the remaining
clones no repeat was found, whereas a deletion of the ORF
sequence was observed (from 5 to 10 bp) and correlated
well with the in vitro concerted integration data
(Figure 3D). Likewise, nearly 50% of the in vitro integration
products present under our conditions contained the speciﬁc
5 bp duplications.
IN can thus catalyze, viral DNA integration in yeast
despite the lack of other viral factors thereby providing a
way to study several parameters of the isolated retroviral
integration step, such as the inﬂuence of viral DNA ends
structure and the involvement of cellular machinery.
Influence of viral LTR structure on integration in yeast
Recently it has been shown that the processing of viral DNA
ends by IN could channel their concerted integration (19). To
determine the role of the viral ends structure and their
integration in a cellular context, we followed IN activity
using different DNA substrates. A DNA substrate that lacked
LTR sequences was ﬁrst used, in which case we recovered a
number of resistant clones identical to the background
(Figure 4) as observed in yeast cells expressing the inactive
D116A IN (Figure 2B). PCR and Southern blot analysis
of the corresponding genomic DNA also gave negative
results indicating that, in contrast with the results obtained
with the substrate containing the two HIV-1 LTRs, no
IN-dependent integration was detected in the absence of
viral sequences.
Since the DNA substrate used in our yeast integration
assay carried the two non-processed LTR ends, it can be
assumed from our results that HIV-1 IN could catalyze
both 30-processing and strand transfer in yeast cells. We
thus sought to determine whether integration in yeast could
be affected by pre-processing the DNA substrate as in
in vitro assays. When the processed DNA was used in our
system, a signiﬁcantly higher number of resistant clones
were obtained in comparison with the blunt-ended DNA
(Figure 4). In addition, the maximum number of selected
clones was attained earlier ( 3 h), suggesting that the global
rate of integration was improved. This result suggests that
processing is a limiting step of the integration and can be
dissociated in time from strand transfer IN activity.
We also conclude that (i) IN is the minimal retroviral
protein needed for DNA integration with two LTRs into
eukaryotic cellular DNA and (ii) some or all of the counter-
parts involved in HIV-1 integration in human infected cells
are also present in yeast. These ﬁndings led us to further
study the cellular mechanisms involved with the retroviral
integration step.
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Figure 2. Selection of zeocin-resistant clones from yeast cells expressing
wt IN (A), D116A IN (B)o rn oI N( C). Yeast cells (109) were grown
from 0 to 5 h after transformation with the DNA integration substrate
containing the two LTRs under non-selective conditions. Cells were plated
on solid medium containing zeocin and after five days the zeocin-resistant
clones were recovered. The results of three independent experiments are
reported.
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RAD51
The last step of proviral integration is the repair of the DNA
gaps ﬂanking the integrated product. Several viral or cellular
proteins have been proposed to be involved in this mecha-
nism. New data reported here suggest that, in addition to
cellular factors, no viral proteins other than IN play a major
role in this repair activity.
Cellular repair systems have been previously proposed to be
important for retroviral infection, such as the proteins belong-
ing to the RAD52 epistasis group (20), but no direct evidence
of their role in the integration step have been shown. Some of
the proteins belonging to the RAD repair system, as RAD18 or
RAD51, have been proposed to function either in the retroviral
integration step in human cells (RAD18), or in the integration
of retrovirus-like elements in yeast (RAD51) (21,22). In con-
trast to the case in human cells, the deletion of RAD51 and
RAD18 in yeast does not lead to deleterious effects. We thus
took into advantage the possibility of using our yeast system to
study the role of those factors speciﬁcally on the isolated inte-
gration step by using the corresponding DNA repair-deﬁcient
mutant yeast stains.
The previously described lethal phenotype observed in a
rad52
  deﬁcient yeast strain (10, 11) further complicated
the analysis of the role of RAD52 in the cellular integration
mechanism but, as an alternative, we performed the integra-
tion assay in haploid yeast strains deﬁcient for either yeast
RAD18 or RAD51 encoding genes (respectively h.rad51
 
and h.rad18
 ). No difference was observed in the number
of zeocin-resistant clones obtained with h.RAD52
+ or
h.rad18
  cells but, in contrast, a signiﬁcantly higher number
of zeocin-resistant clones were obtained in h.rad51
  in an
extremely reproducible way (P-value ¼ 0.03 from ﬁve inde-
pendent experiments, Figure 5). In addition, no such increase
was observed in the yeast cells expressing either the D116A
Figure 3. PCR (A), Southern blot (B) and sequence analysis (C) of the selected zeocin-resistant clones. (A). Aliquots from three different clones obtained from
cells that expressed wt IN (wt1–3), D116A IN (D116A1–3), or no IN (-IN) were subjected to total genomic DNA extraction and PCR using 50-U3-Zeo and 30-U5-
Zeo primers (B). Total genomic DNA was digested by BamH1 restriction enzyme and submitted to Southern blot analysis with (50-
32P) 50-U3-Zeo as a probe. M:
DNA size marker (bp). (C) Total genomic DNA was cut by BamH1 restriction enzyme, ligated, amplified using 50-U3-junction and 30-U5-junction primers and
sequenced using the same primers. The name of the disrupted ORF is mentioned as well as the integration site inside the gene. The 5 bp repeats are underlined,
dotted lines indicate base deletions at the integration site. (D) The sequences of the integrated products obtained either in an in vitro concerted integration assay
[data obtained from Ref. (17)] or from the in vivo yeast integration system were compared. The number of duplications and deletions in both systems are
reported. ’Other duplications’ indicate the number of cases that exhibited duplications comprising sizes from 3 to 6 bp.
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Figure 4. Effect of LTRs on integration catalyzed by IN in yeast.
Experiments similar to those described in Figure 3 were performed using
either the DNA substrate containing the complete LTR sequences (wt LTR),
the 30-processed LTRs (30-OH LTR) or no LTR.
Nucleic Acids Research, 2006, Vol. 34, No. 21 6219mutant or no IN, indicating that the increase of the integration
events observed in the presence of IN was probably not due to
a global stimulation of DNA mobility.
PCR and Southern blot analysis of the genomic DNA of
the clones conﬁrmed that the higher number of clones
obtained with h.rad51
  was due to an increase in integration
events catalyzed by IN (data not shown). Sequencing of
several selected clones in the rad51 deleted strain revealed
a similar ratio of loci presenting the 5 bp duplication com-
pared to the results obtained with the wild type yeast strain
(see Figures 5B and 3D). This indicates that the absence of
RAD51 increased the number of integration events catalyzed
by IN without signiﬁcantly affecting the quality of the inte-
gration reaction products. Taken together, these results sug-
gest a possible negative regulation of integration by the
RAD51 DNA repair system in yeast. To determine whether
this effect was due to a direct inhibition of IN activity by
RAD51 we further analyzed the effect of the human
RAD51 on in vitro integration activity catalyzed by IN.
Human Rad51 interacts with IN and inhibits its in vitro
concerted integration activity
Physical hRAD51-IN interaction was ﬁrst checked by ELISA
experiments using highly puriﬁed enzymes. As reported
in Figure 6A IN was found to bind hRAD51 with notable
efﬁciency (close to the auto-association level of the enzyme).
The interaction was also speciﬁc since no binding of IN was
observed with non coated wells or with the bacterial
class 1 integron recombinase. Nevertheless, as HIV-1 IN is
known for its low solubility, the ﬁxed format of ELISA
could lead to biased results. In addition, we performed
in vitro pull down assays using hRAD51 protein which had
been previously coupled to Afﬁ-gel beads. As shown in
Figure 6B HIV-1 IN was found to associate with Afﬁ-
hRAD51 beads speciﬁcally, since no co-elution was observed
in presence of Afﬁ-BSA beads. It is noteworthy that the Afﬁ-
hRAD51 does not bind all the free IN protein. This could
possibly be due to the fact that Afﬁ-beads contain RAD51
ring structures in which not all the surfaces are accessible
for additional interactions.
Our results indicate that IN and hRAD51 interact in vitro.
We wondered whether this interaction could be responsible of
the IN activity inhibition observed in yeast cells. For this
purpose we analyzed the effects of hRAD51 on in vitro IN
integration activity. Increasing amounts of hRAD51 were
added in a standard concerted integration assay. Under our
conditions hRAD51 caused a strong inhibition of the IN
activity (Figure 7A). Quantiﬁcation of the inhibitory effect
of hRAD51 allowed us to determine an IC50 of 0.5 mM
(Figure 7B). hRAD51 is known to interact with DNA in
presence of ATP (18). Since some ATP may still be present
in the integration labeling reaction it remains to determine the
part of inhibition due to the DNA binding property of RAD51
and/or to its the direct interaction with IN.
DISCUSSION
It has recently been shown that IN exhibits an ability to
complete a concerted integration reaction in vitro similar to
that of puriﬁed PICs from virus-infected cells (8) suggesting
that IN is the minimal requirement to accomplish the whole
nuclear integration process in the cell.
A previous study reported the in vivo activity of avian IN
in eukaryotic cells, indicating that the enzyme was able to
enhance the integration of a transgene by speciﬁc retroviral
integration (23). However, all previous attempts to evaluate
the in vivo activity of HIV-1 IN expressed as the sole viral
protein in eukaryotic cells were unsuccessful in detecting
speciﬁc integration (9). In order to determine whether
HIV-1 IN alone is able to catalyze viral DNA integration,
we chose a simpler model to set up a eukaryotic integration
system based on the use of yeast cells.
Given the strong conservation of genomics and functional
processes between Saccharomyces cerevisiae and human
cells, this yeast has been used to study several steps of the
retroviral life (24–28). In our laboratory, yeast has been
also used as a tool and a model in HIV-1 integration studies
to search for the eukaryotic partners of IN (10,11,15,29–32).
Integration of a two LTR retroviral-like DNA in yeast
Using DNA containing two HIV-1 LTRs and yeast cells
expressing wt HIV-1 IN, we observed that IN alone could
integrate the proviral DNA-like substrate into the nuclear
genome. Several controls such as the use of an inactive
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were analyzed for the structure of their integration loci (B). The number of
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tion to PCR and Southern blot analysis, strongly supported
integration of the DNA substrate into the yeast nuclear
genome catalyzed by HIV-1 IN. Furthermore, the sequencing
of the chromosomal integration locus from the selected
clones displayed the HIV-1 speciﬁc 5 bp repeats at the junc-
tion between LTRs and host DNA, demonstrating that IN
catalyzes integration with the same speciﬁcity in both yeast
and human infected cells. However, deletions were also
observed suggesting that defective integration can also
occur in yeast. We previously demonstrated in vitro that
concerted integration was ascribed to the oligomeric state
of the enzyme since the tetrameric form of IN speciﬁcally
catalyzed the HIV-1 speciﬁc integration leading to 5 bp
duplication (17). This suggests that the defective integration
observed in yeast cells might be due to non-tetrameric or
poorly folded tetramers of IN. In addition, defective inte-
gration could be due to the absence or low levels of speciﬁc
Figure 7. In vitro effect of human RAD51 proteins on integration catalyzed by IN (A) Concerted integration assays performed with 250 nM of IN, 100 ng of
receptor plasmid and 10 ng of donor DNA in absence (lane 2) or in presence of 0.1, 1 or 10 mM of purified human wild type RAD51 (lanes 3, 4 and 5). Lane 1:
substrate alone; S: substrate, IP: integration product, C: concerted integration product, nC: non-concerted integration product. (B) Quantification of the
integration product obtained in presence of increasing amounts of wild type RAD51 proteins. Values are the mean ± SD (error bars) of three independent
experiments.
Figure 6. In vitro interaction between human RAD51 and HIV-1 IN (A) ELISA assay. Experiments were performed with a plate either uncoated or coated with
the reported protein (30 pmol) and revealed with anti-IN antibodies after IN loading (30 pmol of proteins). The signal observed with anti-IN serum on RAD51
coated plate was also reported (-IN) (B) Pull down assay. HIV-IN was subject to affinity pulldown with Affi-beads conjugated to hRAD51 (Affi-RAD51; lanes
1–3) or BSA (Affi-BSA; lanes 4–6). The supernatant (S), wash (W) and SDS eluate (E) from the above reactions were analyzed by SDS–PAGE and Coomassie
blue staining.
Nucleic Acids Research, 2006, Vol. 34, No. 21 6221factors in yeast cells that are normally present in infected
cells. In mammalian cells, PIC could act by preventing
those deleterious events and/or optimizing the basal IN activ-
ity in order to allow highly effective and speciﬁc integration.
Interestingly, no yeast orthologs of human LEDGF/p75, a
recently described IN cofactor, have been found. Since
LEDGF/p75 has been described to stabilize tetramers of IN
(33), the lack of this factor in yeast could lead to a low pro-
portion of tetrameric IN and thus to the partial defective inte-
gration observed.
Taken together our data suggests that in the absence of
other HIV-1 viral factors, IN carries out all the reactions
required for proviral integration in a eukaryotic cell, includ-
ing LTR interaction, nuclear migration (after or before
IN-DNA complex formation), chromosomal targeting, LTR
30-processing and integration.
The stimulation of the integration rate observed when a pre-
processed substrate was used (Figure 4) suggests that
30-processing is a limiting step of integration in our system.
This result indicates that IN recognize a pre-processed subs-
tratebeforetheintegrationstep.Thus,theintracellularprocess-
ing and integration steps can be chronologically distinguished.
Involvement of DNA repair systems in the retroviral
integration step?
As previously described, in addition to viral factors other
cellular proteins (InI1, LEDGF/P75, BAF...) are probably
involved in the integration process (4, 6, 33–36). These fac-
tors may or may not be associated with the PIC and could be
involved in several steps of the integration process such as
nuclear entry and host DNA targeting. However, one step
of the retroviral integration process that still remains obscure
is the repair of the gaps generated during the insertion of viral
DNA into the host cell chromosomes. Full integration of a
viral DNA in the presence of IN as the sole viral protein
reported here indicates that the cellular DNA repair step is
essentially performed by the nuclear machinery, as suggested
by others (37, 38), without ruling out the possible involve-
ment of others viral proteins in the PIC context favoring
this crucial mechanism. Previously, it has been proposed
that the cellular DNA repair systems play a role in this
mechanism (39–41). Recently it has been shown that HR sys-
tems of DNA repair, such as RAD52, can modulate retroviral
infection probably by acting at the integration level (20). To
determine the role of HR systems in the yeast integration
model, we used mutants deﬁcient in proteins of the RAD52
epistasis group. Lethality induced by HIV-1 IN expression
in rad52
  deﬁcient cells strongly suggests, as reported before
(11), that the double strand breaks taking place during
defective or extensive integration events could be repaired
early by this factor explaining why increased retroviral
integration is the ﬁrst major phenotype described for a
RAD52 deﬁciency in mammalian cells (20). Other proteins
of the HR pathway have been previously proposed to play
a role in the infection. We thus studied RAD51, another
factor belonging to the same epistasis group as RAD52, and
also potentially involved in integration. In addition we
analyzed the potential involvement of RAD18 in integration
step as previously proposed (21).
The RAD51 protein down-regulates the integration
catalyzed by HIV-1 IN both in vitro and in yeast
expressing the retroviral enzyme
The lethality induced by the inhibition of RAD51 in
mammalian cells complicated previous studies of the poten-
tial role of this factor in retroviral integration (20). In con-
trast, RAD51 and RAD18 can be deleted in yeast without
affecting the life of the cell allowing us to speciﬁcally
study their involvement in the cellular activity of IN. For
this purpose, we used two yeast strains deﬁcient for both
RAD18 and RAD51. While no effect on integration was
observed when the RAD18 gene was deleted, RAD51
deletion induced a signiﬁcant increase in integration by IN
(Figure 5). This result is consistent with data reported by
Lau et al. (20) indicating that deletion of proteins of the
repair system close to RAD52 led to an increase in cellular
transduction by HIV-1 and suppression of viral infection.
The in vitro inhibition of concerted integration catalyzed
by recombinant IN by the human RAD51, in addition to
the in vitro binding of this factor with IN, strongly suggests
a negative regulation of retroviral integration by RAD51
probably via a direct allosteric effect. hRAD51 could act by
a dual mechanism involving (i) a direct effect on IN protein
and (ii) a competitive effect with IN for its substrates by
DNA binding on cellular or viral integration intermediates.
The detailed biochemical and molecular mechanism involved
in this inhibitory effect remains to be studied.
The differential effect observed with RAD52, RAD51 and
RAD18 repair proteins suggests that each one could play a
different function in proviral integration. The increased
integration observed in mammalian cells deﬁcient for
RAD52 indicates that this factor modulates the number of
integration events probably by repairing the DNA cuts early
before completion of the integration and/or as proposed
before by capping the retroviral DNA ends (20). According
to our results, RAD51 also performs a negative control of
the integration but the mechanism leading to the inhibition
is different than for RAD52 and may involve a direct interac-
tion of IN with RAD51. According to this model, retroviral
integration may be considered as a mutagenic event by the
cell whose answer is to modulate the viral mechanism by
acting on two integration partners: IN and DNA in a competi-
tive ‘struggle for life’. The important link between retroviral
integration and cellular DNA repair processes deserves
further studies in order to establish the biological implication
of the IN-RAD51 interaction in HIV-1 infected cells.
In addition to highlighting several interactions between
HIV-1 integration and cellular mechanisms, our data under-
score the potential use of the yeast S.cerevisiae as a tool of
choice for studying the retroviral integration isolated from
other steps of the infection. The demonstration of IN activity
in yeast indicates that the viral protein may interact with
conserved orthologous factors in human HIV-1 infected
cells as previously described (15, 32). A further advantage
of the yeast model with its highly characterized and accessi-
ble genetics is that it is now possible to dissect the retroviral
cycle by focusing on a unique viral protein, the HIV-1 IN.
Studies of the integration loci reported in our work also
resulted in the possibility to use the yeast system for extended
6222 Nucleic Acids Research, 2006, Vol. 34, No. 21analysis of the host DNA targeting by IN and the role of
additional cellular factors in this mechanism.
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